The Generic Pharmaceutical Association's new CEO, Chip Davis, has big plans to expand the industry's influence in Washington and state capitals. Given the policy successes achieved during his tenure as executive VP of the Pharmaceutical Research and Manufacturers of America, generic firms have good reason to be optimistic.
For Generics Industry, Will Larger Firms Mean Weaker Lobbying?
New CEO Chip Davis wants GPhA sitting at the table in policy debates rather than being on the menu, but industry consolidation means there are fewer dues-paying members to fill the chairs.